Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Michael James Burke MD

Michael James Burke MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology

Member of the Cancer Center


  • A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. (Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE) J Pediatr Hematol Oncol 2016 Jun 13: PMID: 27299599 06/15/2016
  • Minimal Residual Disease in NPM1-Mutated AML. (Burke MJ) N Engl J Med 2016 Feb 4;374(5):481-2 PMID: 26789634 01/21/2016
  • Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. (Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T) Leuk Lymphoma 2016 Jan 4:1-4 PMID: 26726842 01/05/2016
  • Emerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70 PMID: 26616565 12/01/2015
  • Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GM, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL) Biol Blood Marrow Transplant 2015 Dec;21(12):2154-9 PMID: 26327632 PMCID: PMC4654112 09/04/2015
  • Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. (Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM) Pediatr Blood Cancer 2015 May;62(5):743-50 PMID: 25307519 PMCID: PMC4376652 10/14/2014
  • How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. (Burke MJ) Future Oncol 2014 Dec;10(16):2615-27 PMID: 24983955 07/02/2014
  • A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. (Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS) Am J Hematol 2014 Sep;89(9):889-95 PMID: 24891274 PMCID: PMC4134715 06/04/2014
  • Epigenetic modifications in pediatric acute lymphoblastic leukemia. (Burke MJ, Bhatla T) Front Pediatr 2014;2:42 PMID: 24860797 PMCID: PMC4030177 05/27/2014
  • A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). (Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ) Bone Marrow Transplant 2014 Mar;49(3):440-2 PMID: 24317126 12/10/2013
  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR) Bone Marrow Transplant 2014 Feb;49(2):174-8 PMID: 24185590 11/05/2013
  • Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. (Pratt JA, Stricherz MK, Verghese PS, Burke MJ) Pediatr Blood Cancer 2014 Feb;61(2):366-8 PMID: 24038944 09/17/2013
  • How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. (Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C) Am J Hematol 2013 Sep;88(9):826-7 PMID: 23737091 PMCID: PMC3772519 06/06/2013
  • Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5 PMID: 23567175 PMCID: PMC3712759 04/10/2013
  • Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. (Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR) Pediatr Blood Cancer 2013 Apr;60(4):705-10 PMID: 23152304 PMCID: PMC3668778 11/16/2012
  • Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42 PMID: 22960388 PMCID: PMC3530019 09/11/2012
  • Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. (Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL) Blood 2012 May 31;119(22):5201-10 PMID: 22496163 PMCID: PMC3369610 04/13/2012
  • Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8 PMID: 22430088 PMCID: PMC3631589 03/21/2012
  • Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. (Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2012 Jun;18(6):930-6 PMID: 22108570 PMCID: PMC4378716 11/24/2011
  • Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. (Burke MJ, Lindgen B, Verneris MR) Pediatr Blood Cancer 2012 Jun;58(6):840-5 PMID: 21796765 07/29/2011
  • Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3 PMID: 21403127 PMCID: PMC3109547 03/16/2011
  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. (Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ) Bone Marrow Transplant 2011 Jul;46(7):950-5 PMID: 20856210 09/22/2010
  • Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. (Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR) Biol Blood Marrow Transplant 2011 Jun;17(6):831-40 PMID: 20831896 PMCID: PMC3412271 09/14/2010
  • Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. (Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2011 Mar;46(3):368-71 PMID: 20548337 PMCID: PMC3556271 06/16/2010
  • Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62 PMID: 20446122 05/07/2010
  • Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44 PMID: 20302960 PMCID: PMC2904410 03/23/2010
  • Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. (Beck JC, Burke MJ, Tolar J) Pediatr Blood Cancer 2010 Mar;54(3):490-1 PMID: 19908296 11/13/2009
  • Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94 PMID: 19731318 09/05/2009
  • Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. (Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE) Blood 2009 Nov 5;114(19):4293-9 PMID: 19706886 PMCID: PMC2774557 08/27/2009
  • The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5 PMID: 19621426 07/22/2009
  • Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74 PMID: 19204709 02/11/2009
  • Treatment of a CNS relapse while on therapy for Burkitt lymphoma. (Burke MJ, Dayton V) Pediatr Blood Cancer 2009 Feb;52(2):290-2 PMID: 18937319 10/22/2008
  • Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. (Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Jan;43(2):107-13 PMID: 18776928 09/09/2008
  • Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 PMID: 17417796 04/10/2007
  • Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80 PMID: 16900484 08/11/2006
  • Last update: 06/23/2016